Professional
Added to YB: 2025-05-09
Pitch date: 2025-05-05
VRNA [bullish]
Verona Pharma plc
+50.73%
current return
Author Info
No bio for this author
Company Info
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
Market Cap
$9.2B
Pitch Price
$70.93
Price Target
722.50 (+576%)
Dividend
N/A
EV/EBITDA
-175.38
P/E
-104.23
EV/Sales
40.70
Sector
Pharmaceuticals
Category
growth
Buckley Capital Portfolio Holding: Verona Pharma plc
VRNA: Ensifentrine COPD drug now FDA-approved, targeting 4.3M symptomatic US patients. Peak sales potential $4.5B (vs consensus $1-1.5B), 10%+ market share, 50%+ EBITDA margins. Trading at ~1x forward earnings if successful, offering 10x+ return potential. Launch exceeding expectations, substantial upside remains.
Read full article (2 min)